Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 13152
Sealed predictions
- ZMYM4 in dopamine neurons, braak-0.50 (p 0.168) → -0.03 (p 0.946)receipt 13159
Swarm cases
receipt 13159: ZMYM4 in dopamine neurons, braak
- power
- full sample -0.17 (p 0.504, n 18), 95% CI -0.59 to +0.32. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.11 (p 0.658, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.04 (p 0.874, n 18). could be the mix.
- skeptic
- leave-one-out range -0.33 to -0.08, sign flips 0; without severely affected donors -0.17 (p 0.504, n 18). fragile.
- cell type
- strongest in OPCs: -0.63 (p 0.0047, n 18) vs -0.17 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ZMYM4 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ZMYM4 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.40 p 0.155 (needs p < 1.7e-4)
Receipts
loading the receipts